Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Accured Expenses: 2020-2024

Historic Change in Accured Expenses for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $16.4 million.

  • ARS Pharmaceuticals' Change in Accured Expenses rose 152.68% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.6 million, marking a year-over-year increase of 27090.91%. This contributed to the annual value of $16.4 million for FY2024, which is 691.72% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Change in Accured Expenses of $16.4 million as of FY2024, which was up 691.72% from -$2.8 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Change in Accured Expenses peaked at $16.4 million during FY2024, and registered a low of -$10.3 million during FY2022.
  • In the last 3 years, ARS Pharmaceuticals' Change in Accured Expenses had a median value of -$2.8 million in 2023 and averaged $1.1 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 1,155.95% in 2022, then soared by 691.72% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $1.8 million in 2020, then crashed by 45.59% to $974,000 in 2021, then crashed by 1,155.95% to -$10.3 million in 2022, then surged by 73.00% to -$2.8 million in 2023, then spiked by 691.72% to $16.4 million in 2024.